Are NAD+ injections FDA-approved? Compounding status, safety alerts, and provider checks

01

NAD+ is peptide-adjacent, not a peptide

Nicotinamide adenine dinucleotide, commonly shortened to NAD or NAD+, is a coenzyme involved in cellular reactions. It is not made from an amino-acid chain and should not be described as a peptide. It appears on peptide-clinic menus because the same longevity and wellness businesses often sell both categories.

That marketing proximity can create false inferences. Evidence or approval for a peptide drug does not support NAD+ infusions, and biological importance inside cells does not establish that an injected or infused product improves energy, aging, cognition, recovery, or another advertised outcome.

A useful provider comparison should label NAD+ as a separate service and ask separate questions about the product, evidence, pharmacy, route, and regulatory pathway. Broad terms such as cellular optimization or mitochondrial support are claims to investigate, not regulatory classifications.

02

Compounded NAD+ injections are not FDA-approved products

FDA approval attaches to a finished drug application with reviewed evidence, labeling, manufacturing, and controls. A compounded NAD+ vial does not become FDA-approved because a clinician prescribed it, a pharmacy prepared it, the facility registered with FDA, or the ingredient appears in an FDA document.

Compounded drugs can serve patient needs when applicable legal conditions are met, but they do not undergo FDA premarket review for safety, effectiveness, or quality. A clinic should not call compounded NAD+ an approved treatment, an approved generic, or equivalent to a reviewed product.

The question is therefore not only whether NAD+ can be named on a prescription. Consumers need the exact pharmacy, whether it operates under section 503A or 503B, the bulk ingredient identity and grade, the route, the label, and the provider’s evidence for the claimed use.

03

503A Category 1 is an interim status, not approval

FDA’s May 14, 2026 interim 503A categories document lists nicotinamide adenine dinucleotide in Category 1, meaning it was nominated with enough support for FDA to evaluate it and had not been placed in the category for identified significant safety risks. Category 1 is part of an interim enforcement policy while FDA develops the 503A Bulks List.

The listing does not mean FDA determined NAD+ is safe or effective, approved a finished injection, or added it to the final 503A Bulks List through regulation. It also does not erase the other conditions of section 503A, including a valid prescription for an identified patient and ingredient-quality requirements.

Chemical names matter. The same FDA document places a differently named beta-NAD disodium salt trihydrate nomination in Category 3 for inadequate support. A pharmacy answer that says only NAD may conceal a mismatch between the nominated substance and the material actually used.

04

The 503B pathway has produced current enforcement records

In a January 2026 warning letter to GenoGenix, FDA stated that NAD+ did not appear on the 503B Bulks List and was not being used to compound a drug on the shortage list. FDA concluded that the NAD+ products described in that inspection were not eligible for section 503B exemptions on that basis.

That letter is facility- and inspection-specific, but the regulatory explanation is broadly useful: outsourcing-facility registration alone does not authorize every bulk substance. The ingredient must fit the applicable 503B condition at the relevant time, and the facility must meet other requirements involving manufacturing, labeling, reporting, and adverse events.

A separate April 2026 ProRx warning letter cited NAD injection labeling deficiencies and inadequate adverse-event procedures. Warning letters do not prove that every lot from a firm is defective, but they are primary records that should be read by date, location, observation, response, and current follow-up rather than reduced to a badge or rumor.

05

FDA’s sterile-ingredient warning identifies a concrete safety problem

FDA has warned that some compounders used food-grade NAD+ supplied by repackagers to make intravenous products. The agency said ingredients identified as food grade are not suitable for sterile compounding without appropriate processing because microbes and endotoxins can cause harm.

FDA also reported chills, shaking, vomiting, and fatigue after injectable NAD+ use, with some people requiring medical treatment. The agency said those reactions were consistent with excessive endotoxin levels. That wording describes a plausible quality-related signal; it does not establish the cause of every reaction or an event rate for all products.

The warning shows why a generic certificate of analysis or a purity percentage is incomplete. Sterile use raises questions about source grade, microbial and endotoxin controls, container integrity, preparation, testing, transport, and storage. A provider’s claim that an ingredient is natural or pharmaceutical quality needs documentary support tied to the specific batch and compounder.

06

A provider-research checklist for NAD+ services

Ask the clinic to name the finished product and legal compounder before discussing benefits. Match the pharmacy’s address with state licensing records and, if 503B status is claimed, FDA’s outsourcing-facility registry and product reports. Record the date because registration, lists, inspections, and enforcement records change.

Request the exact bulk-substance name, whether the ingredient was intended for sterile drug use, and the basis the pharmacy relies on under its claimed pathway. Do not accept 503A, 503B, FDA-registered, or Category 1 as shorthand for FDA-approved or guaranteed quality.

Then evaluate the clinical claim separately. Ask what human evidence supports the exact route and proposed outcome, who screens for risks, how reactions are handled, and how suspected problems are reported. Treatment decisions belong with appropriately licensed clinicians; seek urgent care for a severe reaction or emergency.

• →Exact product and compounder
• →503A or 503B pathway
• →Precise bulk-substance identity
• →Ingredient suitability for sterile use
• →State and FDA facility records
• →Evidence for the claimed outcome
• →Adverse-event and emergency process